Media Kit

Scroll to top of page

Featured News

Announcement
Ophthalmology

BlueRock Therapeutics exercises exclusive option to license iPSC cell therapy candidate OpCT-001 for treating Primary Photoreceptor Diseases from FUJIFILM Cellular Dynamics and Opsis Therapeutics

Announcement
Neurology

BlueRock’s Phase I study with bemdaneprocel in patients with Parkinson’s disease meets primary endpoint

Announcement

BlueRock Therapeutics and bit.bio announce collaboration and option agreement for the discovery and manufacture of regulatory T cell (Treg) based therapies

Podcast

Podcast: Headlines of the Future | Parkinson's Disease: The Future of Cell and Gene Therapies

See All

Media Library

Media Contact

Video

B-Roll: Lab 1

B-Roll: Lab 2

B-Roll: Lab 3

B-Roll: Lab 4

B-Roll: Lab 5

B-Roll: Lab 6

B-Roll: PSC-Derived Cardiomyocytes

Explore more with BlueRock

Cell Therapy

Our Programs

Our Pipeline

Careers